| 发明名称 | Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector | ||
| 摘要 | This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems. | ||
| 申请公布号 | US8906863(B2) | 申请公布日期 | 2014.12.09 |
| 申请号 | US201113224151 | 申请日期 | 2011.09.01 |
| 申请人 | The Regents of the University of California | 发明人 | Cheng R. Holland;Xing Li |
| 分类号 | A61K38/16;A61K39/21;C07K16/10;C07K14/005;A61K39/29;A61K39/00 | 主分类号 | A61K38/16 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A composition comprising: A capsid protein comprising a portion of HEV ORF 2 protein and a heterologous peptide, wherein the heterologous peptide is inserted into the portion of HEV ORF 2 immediately after the residue corresponding to Tyr485 of an HEV ORF 2 protein of SEQ ID NO:1, 4, 5, or 6; and a heterologous nucleic acid encapsulated in a chimeric HEV virus-like particle (VLP) formed by the capsid protein. | ||
| 地址 | Oakland CA US | ||